On December 9, 2024 EnnoDC, a clinical-stage biotech company pioneering the design and development of first-in-class Dendritic Cell-targeting immunotherapies, reported that new preliminary data of a Phase I/IIa clinical study evaluating its immunotherapy candidate CD40 (Press release, EnnoDC, DEC 9, 2024, View Source [SID1234648898]). HVac in patients with human papillomavirus (HPV16)-associated oropharyngeal carcinoma (OPC), will be presented at the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress 2024, 11-13 December 2024 in Geneva, Switzerland.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster titled, "Preliminary results of a multicentric randomized Phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40.HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)", will be presented byDr Caroline Even, Department Head of the Head and Neck Medical Oncology Unit at Gustave Roussy, on Thursday, 12 December during the poster display session in the foyer mezzanine from 12:30 – 13:30 CET (see the abstract online).
EnnoDC’s first-in-class approach combines the power of vaccines and immunotherapy antibodies to provide targeted immune responses for both cancer and infectious diseases. CD40.HVac is an immunotherapy candidate targeting the E6/E7 antigens of the virus in patients with HPV16+ OPC, the most common form of this disease which accounts for more than 60% of Head & Neck cancers. It is currently evaluated in a Phase I/II multicentric double-blind placebo-controlled dose escalation trial (NCT06007092). The study is being conducted by Gustave Roussy Cancer Campus, European first cancer center.
Christophe Hubert, Chief Executive Officer of EnnoDC, commented:
"These preliminary data provide the first clinical results of our technology inducing HPV-specific CD4+ and CD8+ T cells and showcase for the first time our new immunotherapies which are under development for the treatment of HPV-induced cancers and prostate cancer. We look forward to reporting upcoming results from this trial in the coming months and taking the next steps to develop a new class of treatments for patients that fail to respond to available immunotherapies."
Details of the poster presentation are:
Abstract title: Preliminary results of a multicentric randomized Phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Dr Caroline Even, Department Head of the Head and Neck Medical Oncology Unit at Gustave Roussy
Date/Time: 12 December 2024, 12:30 -13:30 pm CET
Location: Palexpo exhibition centre, Foyer Mezzanine
The ESMO (Free ESMO Whitepaper) IO poster will be available on ENNODC’s corporate website after the poster sessions have been opened.